Tiotropium bromide vs Umeclidinium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT02172287 · Phase 3 · completed

This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).

Reported efficacy

Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)

Result source: NCT02172287

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT02184611 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).

Reported efficacy

Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)

Result source: NCT02184611

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTiotropium bromideUmeclidinium
Moderate or severe exacerbations, annualised rate0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986
—Trial running · NCT06474039
Trough FEV1, change0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052
SGRQ total, change-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915
TDI focal score—Not posted · NCT021722872.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611

Moderate or severe exacerbations, annualised rate

Tiotropium bromide
0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986
Umeclidinium
—Trial running · NCT06474039

Trough FEV1, change

Tiotropium bromide
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788
Umeclidinium
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052

SGRQ total, change

Tiotropium bromide
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470
Umeclidinium
-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915

TDI focal score

Tiotropium bromide
—Not posted · NCT02172287
Umeclidinium
2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Tiotropium bromide: 5 of 5 rows · Umeclidinium: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTiotropium bromide
Rows use multiple source trials
Umeclidinium
Rows use multiple source trials
FEV1 Change 3 h
absolute change · L
0.2 vs -0.05 placebo L @ 24wka,b,c,d
NCT00523991 · Phase 4 · registry result, not featured evidence
0.052 vs 0.048 FF L @ 4wk100/250 µge,a,b,c,d
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more doses
0.072 vs 0.048 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.093 vs 0.048 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.088 vs 0.048 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
10.3%50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
15%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
33.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT00523991 · Phase 4 · registry result, not featured evidence
7.9%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
13.3%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
0%18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
23.2%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23.4%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
13.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
16.1%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
6.3%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
13.7%62.5 mcgg
NCT02184611 · Phase 3
show 25 more results
8.9%125 µg QD
NCT01772147 · Phase 3 · combination
12.3%62.5 µg QD
NCT01772147 · Phase 3 · combination
5.3%62.5 µg
NCT01957163 · Phase 3 · combination
8.7%125 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT02119286 · Phase 3 · combination
5.3%62.5 µg
NCT02119286 · Phase 3 · combination
10.7%125 µg QD
NCT01772134 · Phase 3 · combination
6.9%62.5 µg QD
NCT01772134 · Phase 3 · combination
11.7%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
5%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
8.4%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
8.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.6%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
7.3%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
6.4%50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
10.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT00523991 · Phase 4 · registry result, not featured evidence
2.4%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
10.6%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
11.1%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
10.5%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
3.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.2%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.1%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
1.1%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.4%62.5 mcgg
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
4.9%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
1.9%125 µg
NCT01957163 · Phase 3 · combination
1%125 µg
NCT02119286 · Phase 3 · combination
3.4%62.5 µg
NCT02119286 · Phase 3 · combination
4.9%125 µg QD
NCT01772134 · Phase 3 · combination
2.5%62.5 µg QD
NCT01772134 · Phase 3 · combination
3.6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
1.9%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5.9%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
2%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
2.5%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
—50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
5.9%50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
8.8%50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.7%18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
37.5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
25.6%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
0%50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
3.8%50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
4.2%
NCT00523991 · Phase 4 · registry result, not featured evidence
3%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
0%
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
32.9%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.9%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.8%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
0%150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
0%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
2%5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
3.7%5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
1.8%10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0%tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
2.7%tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.4%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
8.3%62.5 mcgg
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
3%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT01957163 · Phase 3 · combination
1.4%125 µg
NCT02119286 · Phase 3 · combination
3.9%62.5 µg
NCT02119286 · Phase 3 · combination
2.9%125 µg QD
NCT01772134 · Phase 3 · combination
2%62.5 µg QD
NCT01772134 · Phase 3 · combination
6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
3%62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.4%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
6.9%62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
50/250 µg BIDf
nasopharyngitis 18.4%
dysphonia 13.2%
bronchitis 5.1%
NCT01762800 · Phase 4 · registry result, not featured evidence
show 27 more results
50/250 µg BID + 18 µg QD
nasopharyngitis 20.6%
bronchitis 10.3%
dysphonia 8.8%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18 µg QD + 50/250 µg BID
nasopharyngitis 26.7%
dysphonia 8%
bronchitis 6.7%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18μg
chronic obstructive pulmonary disease 37.5% (placebo 43.6%)
bronchitis 7.5% (placebo 5.1%)
insomnia 5% (placebo 5.1%)
NCT01663987 · Phase 4 · registry result, not featured evidence
18 μg
chronic obstructive pulmonary disease 25.6% (placebo 15.4%)
contusion 7.7% (placebo 0%)
oedema peripheral 7.7% (placebo 0%)
NCT01662986 · Phase 4 · registry result, not featured evidence
50/250 µg BID
dysphonia 5.9%
constipation 2%
dry mouth 2%
NCT01751113 · Phase 4 · registry result, not featured evidence
50/250 µg BID + 18 µg QD
dysphonia 9.6%
nasopharyngitis 5.8%
arthralgia 3.8%
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
nasophayngitis 6.7% (placebo 5%)
chronic obstructive pulmonary disease 4.6% (placebo 9.6%)
NCT00523991 · Phase 4 · registry result, not featured evidence
chronic obstructive pulmonary disease 6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 32.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
18 mcg
chronic obstructive pulmonary disease 33.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
2.5 mcg
chronic obstructive pulmonary disease 33.8%
NCT01126437 · Phase 3 · registry result, not featured evidence
10 μg
cough 3.3% (placebo 0%)
headache 3.3% (placebo 3%)
urinary tract infection 3.3% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
40 μg
dry mouth 12.9% (placebo 0%)
dizziness 3.2% (placebo 6.1%)
back pain 0% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
20 μg
back pain 6.3% (placebo 3%)
headache 6.3% (placebo 3%)
cough 3.1% (placebo 0%)
NCT03118765 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 9.3% (placebo 4.1%)
dyspnoea 2% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
18 mcg
nasopharyngitis 4.8% (placebo 4.1%)
dyspnoea 2.1% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
2.5 mcg
dyspnoea 1.4% (placebo 9.5%)
nasopharyngitis 1.4% (placebo 4.1%)
NCT01222533 · Phase 2 · registry result, not featured evidence
1.25 mcg
nasopharyngitis 6.1% (placebo 4.1%)
dyspnoea 3.4% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 10.2%
chronic obstructive pulmonary disease 5.6%
NCT01040403 · Phase 2 · registry result, not featured evidence
10 mcg
nasopharyngitis 6.4%
chronic obstructive pulmonary disease 5.5%
NCT01040403 · Phase 2 · registry result, not featured evidence
tiotropium 5 mcg + olodaterol 10 mcg
chronic obstructive pulmonary disease 3.6%
nasopharyngitis 1.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 5 mcg + olodaterol 5 mcg
chronic obstructive pulmonary disease 7.3%
nasopharyngitis 2.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 10 mcg
nasopharyngitis 3.6%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 5 mcg
nasopharyngitis 7.1%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 10 mcg
nasopharyngitis 7.3%
chronic obstructive pulmonary disease 6.4%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 5 mcg
nasopharyngitis 11%
chronic obstructive pulmonary disease 3.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
62.5 mcgg
upper respiratory tract infection 12.2% (placebo 12.9%)
nasopharyngitis 9.3% (placebo 10.9%)
dizziness 2.9% (placebo 2%)
NCT02184611 · Phase 3
show 23 more results
125 µg QD
nasopharyngitis 5% (placebo 4.5%)
headache 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.5%)
nasopharyngitis 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg
headache 4.4% (placebo 2.9%)
back pain 3.4% (placebo 1.5%)
nasopharyngitis 3.4% (placebo 3.4%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 4.8% (placebo 3.4%)
headache 4.3% (placebo 2.9%)
cough 3.4% (placebo 0.5%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 9.2% (placebo 10.7%)
headache 1.9% (placebo 2.4%)
back pain 1% (placebo 1.9%)
NCT02119286 · Phase 3 · combination
62.5 µg
nasopharyngitis 5.3% (placebo 10.7%)
back pain 3.9% (placebo 1.9%)
headache 3.9% (placebo 2.4%)
NCT02119286 · Phase 3 · combination
125 µg QD
headache 6.3% (placebo 4.9%)
cough 2.4% (placebo 1.5%)
nasopharyngitis 2.4% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.9%)
cough 3.4% (placebo 1.5%)
nasopharyngitis 2.5% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5/25 mcg
nasopharyngitis 8.4%
NCT03034915 · Phase 4 · registry result, not featured evidence
62.5 mcg QD
headache 8.1%
nasopharyngitis 8.1%
NCT02236611 · Phase 4 · registry result, not featured evidence
62.5 mcg+ICS/LABA
nasopharyngitis 13.4% (placebo 14.5%)
headache 3.4% (placebo 6.8%)
cough 2.5% (placebo 4.3%)
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
62.5 mcg QD
headache 5.9%
nasopharyngitis 5.3%
NCT02207829 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 7.5%
nasopharyngitis 6.6%
cough 3.3%
NCT02257385 · Phase 3 · registry result, not featured evidence
62.5/25mcg
headache 6.5% (placebo 6.5%)
nasopharyngitis 5.2% (placebo 6.5%)
NCT02152605 · Phase 3 · registry result, not featured evidence
62.5/25 mcg
headache 6.9%
nasopharyngitis 4%
NCT01879410 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 4 versus Phase 2.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 24 weeks versus 4 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tiotropium bromide

Time to First Exacerbation 0.1 vs 0.33 TIO months50/250 µg BID
time to event · months
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 3 days as posted
show 5 more results
0.16 vs 0.33 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 5 days as posted
0 vs 0 TIO months*50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 0 days as posted
0 vs 0 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 0 days as posted
0.07 vs 0.33 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 2 days as posted
0.03 vs 0 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 1 days as posted
EXACT Total 27.83 vs 28.88 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.92 vs 28.88 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
38.26 vs 28.88 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.35 vs 28.8 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
37.58 vs 28.8 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.87 vs 28.8 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.63 vs 28.4 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.16 vs 28.4 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.57 vs 28.4 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.33 vs 28.93 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
35.92 vs 28.93 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.79 vs 28.93 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.98 vs 28.66 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
34.92 vs 28.66 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
34.03 vs 28.66 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.5 vs 28.8 TIO score @ 24wk50/250 µg BID
absolute value · score
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
32.72 vs 28.8 TIO score @ 24wk50/250 µg BID + 18 µg QD
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.67 vs 28.8 TIO score @ 24wk18 µg QD + 50/250 µg BID
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.76 vs 7.18 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
12.39 vs 7.18 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
13.23 vs 7.18 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.75 vs 6.99 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.86 vs 6.99 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.11 vs 6.99 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.69 vs 6.7 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.79 vs 6.7 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.3 vs 6.7 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.23 vs 6.82 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.66 vs 6.82 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.26 vs 6.82 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.33 vs 6.85 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
10.8 vs 6.85 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
9.89 vs 6.85 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination

+ 113 further endpoints in the CSV export.

Umeclidinium

TDI Focal 2.5 vs 1.6 placebo score @ 24wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
FEV1 Wm0 6 h 0.136 vs 0.011 placebo L @ 0wk62.5 mcg
absolute change · L
NCT02184611 · Phase 3
show 10 more results
0.187 vs 0.034 placebo L @ 12wk62.5 µg
NCT01957163 · Phase 3 · combination
0.184 vs 0.035 placebo L @ 12wk62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
0.235 vs 0.258 Indacaterol + Tiotropium Bromide L @ 12wk62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
0.217 vs 0.052 placebo L @ 12wk125 µg QD
NCT01772147 · Phase 3 · combination
0.175 vs 0.034 placebo L @ 12wk125 µg
NCT01957163 · Phase 3 · combination
0.192 vs 0.032 placebo L @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
0.196 vs 0.052 placebo L @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
0.196 vs 0.032 placebo L @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
0.152 vs 0.017 placebo L @ 12wk125 µg
NCT02119286 · Phase 3 · combination
0.164 vs 0.017 placebo L @ 12wk62.5 µg
NCT02119286 · Phase 3 · combination
CAT Total -1.75 vs -0.26 placebo score @ 4wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
show 2 more results
-2.18 vs -0.08 placebo score @ 12wk62.5 mcg
NCT02184611 · Phase 3
-2 vs -1.32 placebo score @ 24wk62.5 mcg
NCT02184611 · Phase 3
Rescue-free 24-h Period 15.2 vs 1.9 placebo % of time @ 12wk125 µg QD
percent change · % of time
NCT01772147 · Phase 3 · combination
show 1 more result
8.4 vs 1.9 placebo % of time @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
Rescue Puffs -0.7 vs -0.2 placebo puffs @ 12wk125 µg QD
absolute change · puffs
NCT01772147 · Phase 3 · combination
show 3 more results
-0.5 vs -0.2 placebo puffs @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
-0.4 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
-0.5 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
Rescue-free 24 h Periods 11.1 vs 4.9 placebo % of time @ 12wk125 µg QD
absolute change · % of time
NCT01772134 · Phase 3 · combination
show 1 more result
13.3 vs 4.9 placebo % of time @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
TDI Focal 1.68 vs 1.3 UMEC score @ 24wk62.5/25 mcg
absolute value · score
NCT03034915 · Phase 4 · registry result, not featured evidence
TDI Focal 50% (n=806) vs 42% (n=799) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
show 1 more result
56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
E-RS Total -1.52 vs -0.99 UMEC score @ 24wk62.5/25 mcg
absolute change · score
NCT03034915 · Phase 4 · registry result, not featured evidence
show 4 more results
-1.5 vs 0.5 FF score @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Cough Sputum Domain -0.45 vs -0.38 UMEC score @ 24wk62.5/25 mcg
absolute change · score
RS-CSP
NCT03034915 · Phase 4 · registry result, not featured evidence
E-RS 36% (n=809) vs 27% (n=800) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
SGRQ 45% (n=811) vs 41% (n=802) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
show 1 more result
50% (n=489) vs 51% (n=483) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence

+ 12 further endpoints in the CSV export.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Asthmasmall molecule
Reliable signal

NCT00772538 · Phase 3 · completed

The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.

Next expected readout: January 2027 · NCT06679465 (registry estimate)

Reported efficacy

Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Trough FEV1 Response Determined After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Time to First Severe Asthma Exacerbation During the 48-week Treatment of the Pooled Data From the Two Twin Trials 205.416 (NCT00772538) and the Present 205.417 (NCT00776984). (48 weeks): Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) (met)

Result source: NCT00772538

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Phase 2 in Asthmasmall molecule
Partial signal

NCT01573624 · Phase 2 · completed

The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.

Reported efficacy

Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)

Result source: NCT01573624

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTiotropium bromideUmeclidinium
Severe exacerbations, annualised rate—Not reported—Trial running · NCT04651777
Trough FEV1, change0.1 vs -0.0+0.2 vs placebo2.5 mcg once daily · wk 24 · n 247NCT01172808
40 other results
  • 0.2 vs -0.0 2.5 mcg once daily · wk 24 · n 245 · Phase 3 · primary NCT01172821
  • 0.1 vs 0.1 5 µg/day · wk 24 · n 237 · Phase 3 · primary NCT00772538
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 241 · Phase 3 · primary NCT01172808
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 240 · Phase 3 · primary NCT01172821
  • 0.2 vs 0.0 5 µg/day · wk 24 · n 216 · Phase 3 · primary NCT00776984
  • 0.3 vs 0.2 2.5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 2.5 mcg · wk 24 · n 119 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 2.5 mcg · wk 12 · n 135 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 2.5 μg · wk 12 · n 126 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 2.5 mcg · wk 12 · n 151 · Phase 3 · secondary NCT01316380
  • 0.3 vs 0.3 2.5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.1 vs 0.1 2.5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.3 vs 0.2 5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 5 mcg · wk 24 · n 131 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 5 mcg · wk 12 · n 128 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 5 μg · wk 12 · n 130 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 5 mcg · wk 12 · n 152 · Phase 3 · secondary NCT01316380
  • 0.1 vs 0.1 5 µg/day · wk 48 · n 237 · Phase 3 · secondary NCT00772538
  • 0.4 vs 0.3 5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.2 vs 0.1 5 µg/day · wk 48 · n 216 · Phase 3 · secondary NCT00776984
  • 0.2 vs 0.1 5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.2 vs -0.0 1800 μg · wk 0.21 · n 31 · Phase 1 · primary NCT02573155
  • 0.1 vs -0.0 400 μg · wk 0.21 · n 34 · Phase 1 · primary NCT02573155
  • 0.5 vs -0.0 2100 μg · wk 0.21 · n 5 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 1800 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 900 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 400 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 200 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • -0.0 vs -0.0 50 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs 0.1 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 2.5 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01122680
  • 0.2 vs 0.1 5 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 5 µg once daily · wk 4 · n 143 · Phase 2 · secondary NCT01233284
  • 0.3 vs 0.1 5 µg once daily · wk 4 · n 90 · Phase 2 · secondary NCT01152450
  • 0.4 vs 0.3 5 mcg · wk 4 · n 77 · Phase 2 · secondary NCT01122680
  • 0.3 vs 0.1 2.5 µg twice daily · wk 4 · n 89 · Phase 2 · secondary NCT01152450
  • 0.2 vs 0.1 1.25 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 1.25 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 1.25 mcg · wk 4 · n 73 · Phase 2 · secondary NCT01122680
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
ACQ-5, change—Not reported—Trial running · NCT04651777
OCS dose reduction—Not reported—Trial running · NCT04651777

Severe exacerbations, annualised rate

Tiotropium bromide
—Not reported
Umeclidinium
—Trial running · NCT04651777

Trough FEV1, change

Tiotropium bromide
0.1 vs -0.0+0.2 vs placebo2.5 mcg once daily · wk 24 · n 247NCT01172808
40 other results
  • 0.2 vs -0.0 2.5 mcg once daily · wk 24 · n 245 · Phase 3 · primary NCT01172821
  • 0.1 vs 0.1 5 µg/day · wk 24 · n 237 · Phase 3 · primary NCT00772538
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 241 · Phase 3 · primary NCT01172808
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 240 · Phase 3 · primary NCT01172821
  • 0.2 vs 0.0 5 µg/day · wk 24 · n 216 · Phase 3 · primary NCT00776984
  • 0.3 vs 0.2 2.5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 2.5 mcg · wk 24 · n 119 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 2.5 mcg · wk 12 · n 135 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 2.5 μg · wk 12 · n 126 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 2.5 mcg · wk 12 · n 151 · Phase 3 · secondary NCT01316380
  • 0.3 vs 0.3 2.5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.1 vs 0.1 2.5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.3 vs 0.2 5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 5 mcg · wk 24 · n 131 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 5 mcg · wk 12 · n 128 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 5 μg · wk 12 · n 130 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 5 mcg · wk 12 · n 152 · Phase 3 · secondary NCT01316380
  • 0.1 vs 0.1 5 µg/day · wk 48 · n 237 · Phase 3 · secondary NCT00772538
  • 0.4 vs 0.3 5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.2 vs 0.1 5 µg/day · wk 48 · n 216 · Phase 3 · secondary NCT00776984
  • 0.2 vs 0.1 5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.2 vs -0.0 1800 μg · wk 0.21 · n 31 · Phase 1 · primary NCT02573155
  • 0.1 vs -0.0 400 μg · wk 0.21 · n 34 · Phase 1 · primary NCT02573155
  • 0.5 vs -0.0 2100 μg · wk 0.21 · n 5 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 1800 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 900 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 400 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 200 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • -0.0 vs -0.0 50 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs 0.1 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 2.5 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01122680
  • 0.2 vs 0.1 5 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 5 µg once daily · wk 4 · n 143 · Phase 2 · secondary NCT01233284
  • 0.3 vs 0.1 5 µg once daily · wk 4 · n 90 · Phase 2 · secondary NCT01152450
  • 0.4 vs 0.3 5 mcg · wk 4 · n 77 · Phase 2 · secondary NCT01122680
  • 0.3 vs 0.1 2.5 µg twice daily · wk 4 · n 89 · Phase 2 · secondary NCT01152450
  • 0.2 vs 0.1 1.25 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 1.25 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 1.25 mcg · wk 4 · n 73 · Phase 2 · secondary NCT01122680
Umeclidinium
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539

ACQ-5, change

Tiotropium bromide
—Not reported
Umeclidinium
—Trial running · NCT04651777

OCS dose reduction

Tiotropium bromide
—Not reported
Umeclidinium
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Tiotropium bromide: 9 of 9 rows · Umeclidinium: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTiotropium bromide
Rows use multiple source trials
Umeclidinium
Rows use multiple source trials
Evening PEF
absolute change · L/min
1.101 vs -10.357 placebo L/min @ 52wk2.5 µg once dailya,b,c,d,e
NCT01340209 · Phase 3 · registry result, not featured evidence
show 1 more dose
6.041 vs -10.357 placebo L/min @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
23.7 vs -5.2 FF L/min100 mcg + 125 mcga,b,c,d,e
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more doses
11.1 vs -5.2 FF L/min100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
17.7 vs -5.2 FF L/min100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
12.1 vs -5.2 FF L/min100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
16 vs -5.2 FF L/min100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
FEV1 Trough
absolute change · L
No placebo or comparator arm
0.207 L @ 4wk5 µg QDa,c,d,f
NCT01696071 · Phase 2 · registry result, not featured evidence
show 1 more dose
0.203 L @ 4wk2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
0.0444 L @ 2wk100 mcg + 125 mcga,c,d,f
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more doses
0.026 L @ 2wk100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.051 L @ 2wk100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.032 L @ 2wk100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0385 L @ 2wk100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Morning PEF
absolute change · L/min
24.31 vs 1.953 placebo L/min @ 4wk5 µg once dailya,g,d
NCT01152450 · Phase 2 · registry result, not featured evidence
show 1 more dose
23.281 vs 1.953 placebo L/min @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
10.5 vs -14.2 FF L/min @ 4wk100/250 µga,g,d
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more doses
5.5 vs -14.2 FF L/min @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
3.9 vs -14.2 FF L/min @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
7.6 vs -14.2 FF L/min @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Morning PEF
absolute change · L
26.362 vs 20.824 placebo L @ 48wk2.5 mcga,b,c,h,e
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 1 more dose
29.598 vs 20.824 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
20 vs -2.9 FF L100 mcg + 125 mcga,b,c,h,e
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more doses
13 vs -2.9 FF L100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
19 vs -2.9 FF L100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
14.5 vs -2.9 FF L100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
15.7 vs -2.9 FF L100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Rescue Puffs
absolute change · Puffs
-0.29 vs -0.25 placebo Puffs @ 52wk2.5 µg once dailya,b,g,d,i
NCT01340209 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.22 vs -0.25 placebo Puffs @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
-0.2 vs 0.6 FF Puffs @ 4wk100/250 µga,b,g,d,i
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more doses
0 vs 0.6 FF Puffs @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.4 vs 0.6 FF Puffs @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.5 vs 0.6 FF Puffs @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
11%5 µg/dayj
NCT00772538 · Phase 3
show 39 more results
—
NCT00565266 · Phase 3 · combination · Asthma · phase 3
4.4%2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
3.7%5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.7%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
3.1%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
8%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
4.4%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.8%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
7%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
7%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
5%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
8.7%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
4.7%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
5.1%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
3.2%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
1.9%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
9.6%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
—5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—100 mcg + 125 mcgk
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
5.9%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
5.1%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
6.5%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
5.8%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
2.5%5 µg/dayj
NCT00772538 · Phase 3
show 39 more results
—
NCT00565266 · Phase 3 · combination · Asthma · phase 3
—2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
—5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
1.5%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.9%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.8%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.5%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
3%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.8%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.8%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
1.3%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.6%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.9%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
—5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—100 mcg + 125 mcgk
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
7.6%5 µg/dayj
NCT00772538 · Phase 3
show 39 more results
1.5%
NCT00565266 · Phase 3 · combination · Asthma · phase 3
2.2%2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.7%5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
1.5%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
3.1%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
1.6%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
2.2%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.8%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
1.5%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
3.5%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
3.5%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.9%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
1.5%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
2.7%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
2.8%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.6%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
8.7%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0%5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
1%2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
1.4%5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0%1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0%2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
2.2%5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
1.3%5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
1.3%1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0%2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
2.9%400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%100 mcg + 125 mcgk
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
0%100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.6%100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.7%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.9%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
2.2%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
5 µg/dayj
asthma 34.6% (placebo 44.6%)
peak expiratory flow rate decreased 20.7% (placebo 26.1%)
nasopharyngitis 8% (placebo 9%)
NCT00772538 · Phase 3
show 28 more results
urgent care visit due to asthma 1%
NCT00565266 · Phase 3 · combination · Asthma · phase 3
2.5 mcg
asthma 36.3% (placebo 43.5%)
peak expiratory flow rate decreased 23% (placebo 20.6%)
nasopharyngitis 11.1% (placebo 9.9%)
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
5 mcg
asthma 34.1% (placebo 43.5%)
peak expiratory flow rate decreased 21.5% (placebo 20.6%)
respiratory tract infection 9.6% (placebo 12.2%)
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
2.5 mcg
asthma 14.7% (placebo 21.6%)
peak expiratory flow rate decreased 11% (placebo 14.9%)
nasopharyngitis 4.4% (placebo 8.2%)
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
5 mcg
asthma 16.9% (placebo 21.6%)
peak expiratory flow rate decreased 11.5% (placebo 14.9%)
nasopharyngitis 4.6% (placebo 8.2%)
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
2.5 mcg
asthma 21.6% (placebo 23.2%)
nasopharyngitis 10.4% (placebo 12.3%)
respiratory tract infection viral 8.8% (placebo 8%)
NCT01257230 · Phase 3 · registry result, not featured evidence
5 mcg
asthma 16.4% (placebo 23.2%)
nasopharyngitis 14.9% (placebo 12.3%)
respiratory tract infection viral 7.5% (placebo 8%)
NCT01257230 · Phase 3 · registry result, not featured evidence
2.5 μg
asthma 11% (placebo 10.4%)
peak expiratory flow rate decreased 7.1% (placebo 9.6%)
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
5 μg
asthma 10.8% (placebo 10.4%)
peak expiratory flow rate decreased 3.8% (placebo 9.6%)
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
2.5 µg once daily
nasopharyngitis 44.7% (placebo 42.1%)
asthma 29.8% (placebo 36.8%)
bronchitis 13.2% (placebo 7%)
NCT01340209 · Phase 3 · registry result, not featured evidence
5 µg once daily
nasopharyngitis 48.2% (placebo 42.1%)
asthma 28.1% (placebo 36.8%)
peak expiratory flow rate decreased 15.8% (placebo 21.1%)
NCT01340209 · Phase 3 · registry result, not featured evidence
2.5 mcg once daily
asthma 13.7% (placebo 21.6%)
peak expiratory flow rate decreased 10.7% (placebo 19%)
nasopharyngitis 6.9% (placebo 8.2%)
NCT01172808 · Phase 3 · registry result, not featured evidence
5 mcg once daily
asthma 22.7% (placebo 21.6%)
peak expiratory flow rate decreased 12.9% (placebo 19%)
nasopharyngitis 8.3% (placebo 8.2%)
NCT01172808 · Phase 3 · registry result, not featured evidence
2.5 mcg once daily
asthma 17.1% (placebo 21.3%)
nasopharyngitis 12.1% (placebo 10.2%)
peak expiratory flow rate decreased 8.2% (placebo 11%)
NCT01172821 · Phase 3 · registry result, not featured evidence
5 mcg once daily
asthma 19.8% (placebo 21.3%)
peak expiratory flow rate decreased 9.9% (placebo 11%)
nasopharyngitis 7.5% (placebo 10.2%)
NCT01172821 · Phase 3 · registry result, not featured evidence
2.5 mcg
asthma 15.6% (placebo 12.3%)
peak expiratory flow rate decreased 5.8% (placebo 3.9%)
NCT01316380 · Phase 3 · registry result, not featured evidence
5 mcg
asthma 11% (placebo 12.3%)
peak expiratory flow rate decreased 3.9% (placebo 3.9%)
NCT01316380 · Phase 3 · registry result, not featured evidence
5 µg/day
asthma 37.9% (placebo 47.9%)
peak expiratory flow rate decreased 20.1% (placebo 27.4%)
nasopharyngitis 14.6% (placebo 15.4%)
NCT00776984 · Phase 3 · registry result, not featured evidence
2.5 µg once daily
headache 7.8% (placebo 4.3%)
NCT01152450 · Phase 2 · registry result, not featured evidence
5 µg once daily
headache 5.6% (placebo 4.3%)
NCT01152450 · Phase 2 · registry result, not featured evidence
2100 μg
nasopharyngitis 40% (placebo 8.3%)
bronchitis viral 20% (placebo 0%)
feeling hot 20% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
1800 μg
headache 16.7% (placebo 25%)
nausea 16.7% (placebo 0%)
neck pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
1800 μg
headache 9.7% (placebo 25%)
chronic obstructive pulmonary disorder 3.2% (placebo 0%)
nasopharyngitis 3.2% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
900 μg
headache 33.3% (placebo 25%)
back pain 16.7% (placebo 0%)
cough 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
400 μg
headache 33.3% (placebo 25%)
back pain 16.7% (placebo 0%)
neck pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
400 μg
headache 14.7% (placebo 25%)
chronic obstructive pulmonary disorder 5.9% (placebo 0%)
nasopharyngitis 2.9% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
200 μg
abscess oral 16.7% (placebo 0%)
chest discomfort 16.7% (placebo 8.3%)
chest pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
50 μg
headache 50% (placebo 25%)
nasopharyngitis 50% (placebo 8.3%)
back pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
100 mcg + 125 mcgk
headache 2.3%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 18 more results
100 mcg + 15.6 mcg
headache 2.2%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 250 mcg
headache 3.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 31.25 mcg
headache 1.1%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 62.5 mcg
headache 2.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
31.25 µg BID
headache 4.5% (placebo 1.6%)
nasopharyngitis 1.5% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
250 µg QD
headache 4.4% (placebo 1.6%)
product taste abnormal 3.7% (placebo 0%)
nasopharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
125 µg QD
headache 3.1% (placebo 1.6%)
product taste abnormal 3.1% (placebo 0%)
nasopharyngitis 2.3% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
62.5 µg QD
headache 3.8% (placebo 1.6%)
pharyngitis 3.8% (placebo 0.8%)
nasopharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.5 µg QD
headache 2.9% (placebo 1.6%)
product taste abnormal 1.4% (placebo 0%)
pharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg BID
nasopharyngitis 3.2% (placebo 0.8%)
headache 1.6% (placebo 1.6%)
pharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg QD
headache 3.8% (placebo 1.6%)
nasopharyngitis 2.3% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.25 mcg QD
nasopharyngitis 10.1% (placebo 11.9%)
headache 6.5% (placebo 7.7%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
62.5 mcg QD
nasopharyngitis 9.4% (placebo 11.9%)
headache 8.6% (placebo 7.7%)
upper respiratory tract infection 4.3% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fAssessment timepoints differ: 4 weeks versus 2 weeks.
  7. gPopulation context differs: registered conditions differ.
  8. hTreatment context differs: add on versus combination.
  9. iAssessment timepoints differ: 52 weeks versus 4 weeks.
  10. jPopulation comparability has not been reviewed for 39 of these studies.
  11. kPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tiotropium bromide

FEV1 Peak 0.395 vs 0.225 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 30 more results
0.474 vs 0.351 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.287 vs 0.252 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.507 vs 0.373 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.55 vs 0.438 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.289 vs 0.053 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.287 vs 0.075 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.293 vs 0.134 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.29 vs 0.185 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.244 vs 0.116 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.546 vs 0.489 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.401 vs 0.315 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.367 vs 0.295 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.389 vs 0.225 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.477 vs 0.351 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.391 vs 0.252 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.547 vs 0.373 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.528 vs 0.438 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.25 vs 0.053 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.244 vs 0.075 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.262 vs 0.134 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.401 vs 0.248 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.397 vs 0.245 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.272 vs 0.185 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.304 vs 0.116 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.468 vs 0.337 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.602 vs 0.489 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.469 vs 0.337 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.261 vs 0.185 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.255 vs 0.116 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.556 vs 0.489 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
Time to First Severe Exacerbation NA vs NA placebo months @ 24wk2.5 mcg once daily
time to event · months
NCT01172808 · Phase 3 · registry result, not featured evidence
show 7 more results
NA vs NA placebo months2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months @ 48wk5 µg/day
NCT00772538 · Phase 3
NA vs NA placebo months @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FVC Peak 0.325 vs 0.215 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 30 more results
0.43 vs 0.361 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.201 vs 0.244 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.419 vs 0.331 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.37 vs 0.279 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.219 vs 0.045 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.181 vs 0.071 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.231 vs 0.126 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.253 vs 0.202 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.163 vs 0.092 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.554 vs 0.546 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.445 vs 0.355 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.462 vs 0.337 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.307 vs 0.215 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.413 vs 0.361 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.275 vs 0.244 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.403 vs 0.331 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.342 vs 0.279 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.148 vs 0.045 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.16 vs 0.071 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.183 vs 0.126 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.416 vs 0.323 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.42 vs 0.305 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.239 vs 0.202 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.229 vs 0.092 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.35 vs 0.302 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.548 vs 0.546 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.38 vs 0.302 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.208 vs 0.202 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.171 vs 0.092 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.554 vs 0.546 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
FVC Trough 0.246 vs 0.154 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 28 more results
0.341 vs 0.28 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.094 vs 0.141 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.345 vs 0.281 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.085 vs 0.122 placebo L @ 52wk2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.086 vs -0.039 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.039 vs -0.048 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.107 vs 0.06 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.076 vs 0.004 placebo L @ 4wk2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.381 vs 0.357 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.157 vs 0.022 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.173 vs 0.062 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.206 vs 0.154 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.333 vs 0.28 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.15 vs 0.141 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.316 vs 0.281 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.204 vs 0.122 placebo L @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.036 vs -0.039 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.035 vs -0.048 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.15 vs 0.044 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.142 vs 0.072 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.113 vs 0.06 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.102 vs 0.004 placebo L @ 4wk5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.168 vs 0.112 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.4 vs 0.357 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.179 vs 0.112 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.109 vs 0.06 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.058 vs 0.004 placebo L @ 4wk1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.375 vs 0.357 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
FEV1 AUC0-3 0.192 vs -0.033 placebo L @ 24wk2.5 mcg once daily
absolute change · L
NCT01172808 · Phase 3 · registry result, not featured evidence
show 5 more results
0.315 vs 0.229 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.289 vs 0.217 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.163 vs -0.033 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.307 vs 0.164 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.31 vs 0.172 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FVC AUC(0-3 0.105 vs 0.145 placebo L @ 12wk2.5 mcg
absolute change · L
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
show 22 more results
0.33 vs 0.24 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.262 vs 0.175 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.092 vs -0.066 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.101 vs 0 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.134 vs 0.087 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.047 vs -0.028 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.417 vs 0.413 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.328 vs 0.23 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.344 vs 0.223 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.182 vs 0.145 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.311 vs 0.24 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.227 vs 0.175 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.041 vs -0.066 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.061 vs 0 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.295 vs 0.187 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.299 vs 0.19 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.11 vs 0.087 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.11 vs -0.028 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.429 vs 0.413 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.097 vs 0.087 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.036 vs -0.028 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.441 vs 0.413 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
FEV1 Morning 0.209 vs 0.191 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 11 more results
0.259 vs 0.236 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.142 vs 0.174 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.101 vs 0.021 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.099 vs 0.02 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.062 vs -0.055 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.126 vs 0.191 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.221 vs 0.236 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.125 vs 0.174 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.073 vs 0.021 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.084 vs 0.02 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.096 vs 0.006 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FEV1 Evening 0.142 vs 0.167 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 11 more results
0.208 vs 0.202 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.104 vs 0.155 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.065 vs 0 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.066 vs -0.002 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.075 vs -0.05 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.092 vs 0.167 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.159 vs 0.202 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.094 vs 0.155 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.039 vs 0 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.064 vs -0.002 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.122 vs -0.015 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
PEF Variability -0.942% (n=135) vs -1.204% (n=131) placebo @ 24wk2.5 mcg
absolute change · percentage points
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 18 more results
-0.048% (n=135) vs -0.32% (n=131) placebo @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.8% (n=136) vs 0.15% (n=127) placebo @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
-0.968% (n=114) vs -0.367% (n=56) placebo @ 52wk2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
-1.958% (n=244) vs -1.4% (n=237) placebo @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
-1.401% (n=237) vs -0.448% (n=232) placebo @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
-0.711% (n=146) vs -0.171% (n=142) placebo @ 4wk2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
-0.714% (n=237) vs -0.997% (n=222) placebo @ 24wk5 µg/day
NCT00772538 · Phase 3
-1.038% (n=135) vs -1.204% (n=131) placebo @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.899% (n=135) vs -0.32% (n=131) placebo @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.352% (n=125) vs 0.15% (n=127) placebo @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.197% (n=114) vs -0.367% (n=56) placebo @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.18% (n=234) vs -1.4% (n=237) placebo @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
-0.627% (n=234) vs -0.448% (n=232) placebo @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
-0.611% (n=216) vs -1.808% (n=232) placebo @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
-0.248% (n=144) vs -0.171% (n=142) placebo @ 4wk5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.685% (n=88) vs 0.296% (n=91) placebo @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.619% (n=89) vs 0.296% (n=91) placebo @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
-0.285% (n=146) vs -0.171% (n=142) placebo @ 4wk1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
Asthma Exacerbation Free 51.1% (n=237) vs 38.3% (n=222) placebo @ 48wk5 µg/day
responder rate · % of participants
0 exacerbations
NCT00772538 · Phase 3 · converted to % from 121 Participants as posted
Asthma Exacerbation Occurrence 48.9% (n=237) vs 61.7% (n=222) placebo @ 48wk5 µg/day
event count · % of participants
NCT00772538 · Phase 3 · converted to % from 116 Participants as posted
show 1 more result
50.9% (n=216) vs 64.7% (n=232) placebo @ 48wk*5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence · converted to % from 110 Participants as posted
Severe Asthma Exacerbation Occurrence 22.4% (n=237) vs 30.6% (n=222) placebo @ 48wk5 µg/day
event count · % of participants
NCT00772538 · Phase 3 · converted to % from 53 Participants as posted
show 1 more result
31.9% (n=216) vs 34.9% (n=232) placebo @ 48wk*5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence · converted to % from 69 Participants as posted

+ 68 further endpoints in the CSV export.

Umeclidinium

FEV1 Wm0 24 h 0.077 vs -0.025 placebo L @ 2wk31.25 µg QD
absolute change · L
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
0.043 vs -0.025 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.048 vs -0.025 placebo L @ 2wk250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.094 vs -0.025 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.092 vs -0.025 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.06 vs -0.025 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.097 vs -0.025 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Evening PEF Change L/Min 1.5 vs -5.1 placebo L/min @ 2wk31.25 µg QD
absolute change · L/min
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
8.7 vs -5.1 placebo L/min @ 2wk31.25 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3 vs -5.1 placebo L/min @ 2wk250 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.8 vs -5.1 placebo L/min @ 2wk125 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
-0.9 vs -5.1 placebo L/min @ 2wk62.5 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
10 vs -5.1 placebo L/min @ 2wk15.6 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.5 vs -5.1 placebo L/min @ 2wk15.6 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
FEV1 Change 3 h 0.3663 vs 0.1768 placebo L @ 24wk31.25 mcg QD
absolute change · L
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
show 5 more results
0.052 vs 0.048 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.072 vs 0.048 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.093 vs 0.048 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.088 vs 0.048 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.3744 vs 0.1768 placebo L @ 24wk62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
E-RS Total -1.5 vs 0.5 FF score @ 4wk100/250 µg
absolute change · score
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tiotropium bromide's landscape · Umeclidinium's landscape